Yan Xie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3572399/publications.pdf

Version: 2024-02-01

48	7,088	136950	214800
papers	citations	32 h-index	47 g-index

54	54	54	7233
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Long-term cardiovascular outcomes of COVID-19. Nature Medicine, 2022, 28, 583-590.	30.7	1,029
2	High-dimensional characterization of post-acute sequelae of COVID-19. Nature, 2021, 594, 259-264.	27.8	961
3	Analysis of the Global Burden of Disease study highlights the global, regional, and national trendsÂof chronic kidney disease epidemiology from 1990 to 2016. Kidney International, 2018, 94, 567-581.	5.2	592
4	Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine, 2022, 28, 1461-1467.	30.7	460
5	Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 311-321.	11.4	289
6	Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2016, 27, 3153-3163.	6.1	263
7	The 2016 global and national burden of diabetes mellitus attributable to PM 2Â·5 air pollution. Lancet Planetary Health, The, 2018, 2, e301-e312.	11.4	240
8	Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2018, 29, 218-230.	6.1	225
9	Burden of Cause-Specific Mortality Associated With PM_{2.5} Air Pollution in the United States. JAMA Network Open, 2019, 2, e1915834.	5.9	205
10	Kidney Outcomes in Long COVID. Journal of the American Society of Nephrology: JASN, 2021, 32, 2851-2862.	6.1	200
11	Risks of mental health outcomes in people with covid-19: cohort study. BMJ, The, 2022, 376, e068993.	6.0	199
12	Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nature Communications, 2021, 12, 6571.	12.8	196
13	Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open, 2017, 7, e015735.	1.9	194
14	Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 14-25.	4.5	158
15	High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1784-1793.	4.5	157
16	Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ: British Medical Journal, 2019, 365, l1580.	2.3	146
17	Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International, 2017, 91, 1482-1494.	5.2	134
18	Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study. Lancet Planetary Health, The, 2017, 1, e267-e276.	11.4	131

#	Article	IF	Citations
19	Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. BMJ, The, 2020, 371, m4677.	6.0	129
20	Changes in the US Burden of Chronic Kidney Disease From 2002 to 2016. JAMA Network Open, 2018, 1, e184412.	5.9	106
21	Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney International, 2018, 93, 741-752.	5.2	104
22	Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney International, 2016, 89, 886-896.	5.2	101
23	Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. American Journal of Kidney Diseases, 2020, 75, 497-507.	1.9	86
24	Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: Cohort study. Environment International, 2021, 154, 106564.	10.0	70
25	Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. Diabetes Care, 2020, 43, 2859-2869.	8.6	68
26	Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution. BMJ Open, 2019, 9, e022450.	1.9	58
27	Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 603-613.	4.5	56
28	Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018. JAMA Network Open, 2021, 4, e2033953.	5.9	53
29	Rate of Kidney Function Decline and Risk of Hospitalizations in Stage 3A CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1946-1955.	4.5	51
30	Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality. American Journal of Kidney Diseases, 2016, 68, 219-228.	1.9	45
31	Geographic Variation and US County Characteristics Associated With Rapid Kidney Function Decline. Kidney International Reports, 2017, 2, 5-17.	0.8	42
32	The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study. BMJ Global Health, 2020, 5, e002063.	4.7	40
33	Ambient Fine Particulate Matter Air Pollution and Risk of Weight Gain and Obesity in United States Veterans: An Observational Cohort Study. Environmental Health Perspectives, 2021, 129, 47003.	6.0	32
34	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2021, 181, 1043.	5.1	32
35	Renal Function Trajectories in Patients with Prior Improved eGFR Slopes and Risk of Death. PLoS ONE, 2016, 11, e0149283.	2.5	29
36	Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open, 2021, 11, e047369.	1.9	29

#	Article	IF	Citations
37	Comparative Effectiveness of the Sodiumâ€“Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. Diabetes Care, 2020, 43, 2785-2795.	8.6	26
38	Serum phosphorus levels and risk of incident dementia. PLoS ONE, 2017, 12, e0171377.	2.5	25
39	Diabetes Minimally Mediated the Association Between PM2.5 Air Pollution and Kidney Outcomes. Scientific Reports, 2020, 10, 4586.	3.3	21
40	Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodiumâ€Glucose Cotransporterâ€2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. Journal of the American Heart Association, 2021, 10, e020237.	3.7	19
41	The association of proton pump inhibitors and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2018, 27, 182-187.	2.0	16
42	Blood urea nitrogen and risk of insulin use among people with diabetes. Diabetes and Vascular Disease Research, 2018, 15, 409-416.	2.0	15
43	County-Level Contextual Characteristics and Disparities in Life Expectancy. Mayo Clinic Proceedings, 2021, 96, 92-104.	3.0	11
44	Monocyte count modifies the association between chronic kidney disease and risk ofÂdeath. Clinical Nephrology, 2018, 90, 194-208.	0.7	5
45	Development and validation of lupus nephritis case definitions using United States veterans affairs electronic health records. Lupus, 2021, 30, 518-526.	1.6	4
46	A prognostic scoring system for arm exercise stress testing. Open Heart, 2016, 3, e000333.	2.3	2
47	The Authors Reply. Kidney International, 2017, 92, 515-516.	5.2	2
48	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetesâ€”Reply. JAMA Internal Medicine, 2021, , .	5.1	0